JCJulian M. Carosi

Julian M. Carosi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julian M. Carosi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A genetically encoded system to purify senescent cells

    by Hourieh Tousian, Rachael A. Protzman, Timothy J. Sargeant, Julian M. Carosi

  • Open Access

    SenLect: a genetically encoded system to purify senescent cells

    by Hourieh Tousian, Rachael A Protzman, Timothy J. Sargeant, Julian M. Carosi

    Cellular senescence is a state of irreversible cell cycle arrest that prevents cancer and promotes biological ageing and inflammation. The molecular landscape of cellular senescence has been met with conflicting findings, likely due to contamination of senescent cells by neighbouring proliferating cells. Here, we developed a genetically encoded and tractable system to purify senescent cells in culture termed ‘SenLect’ ( Sen escence se Lect ion). SenLect is a genetic cassette that expresses mCherry-2A-PuroR under the control of the miR-146a senescence-activated promoter, which provides senescent cells with a selective advantage over proliferating cells in the presence of the antibiotic puromycin. We validated this one-step system in primary HUVECs and HeLa cervical cancer cells to purify live senescent cells following DNA damage (UV irradiation, hydrogen peroxide, and doxorubicin) and cell-cycle inhibition (palbociclib). Puromycin-selected cells were enriched for various senescence-related phenotypes, including cell cycle arrest, increased cell size, and lysosomal β-galactosidase activity. By using SenLect to remove proliferating cells, we uncovered how the proteome is rewired during senescence induced by palbociclib. This improved the detection of protein signatures linked to the senescence-associated secretory phenotype (SASP), and metabolic shifts from mitochondrial respiration to glycolysis, and from nucleotide synthesis to catabolism. It also revealed sub-proteome level rewiring of organelles such as mitochondria, lysosomes and the nucleolus, as well as protein cohorts like kinases and core-essential proteins. SenLect provides a consistent and reliable method for isolating senescent cells that is suitable for downstream applications or analyses.

  • Open Access

    Cell‐Type‐Specific Autophagy in Human Leukocytes

    by Linh V. P. Dang, Alexis Martin, Julian M. Carosi, Jemima Gore, Sanjna Singh, Timothy J. Sargeant

    Autophagy is a naturally conserved mechanism crucial for degrading and recycling damaged organelles and proteins to support cell survival. This process slows biological aging and age‐related disease in preclinical models. However, there has been little translation of autophagy to the clinic, and we have identified a lack of measurement tools for physiological human autophagy as a barrier. To address this, we have previously developed a direct measurement tool for autophagy in pooled human peripheral blood mononuclear cells (PBMCs) in the context of whole blood. In order to better understand how autophagy behaves and changes in humans, we measured human autophagic flux using flow cytometry in 19 cell subpopulations in whole blood to retain physiological flux. Autophagic flux was different between different cell types, being different within different monocyte, B lymphocyte, natural killer cell, and T lymphocyte subtypes. Autophagic flux also varied with sex, being higher in monocytes in females compared with males. In keeping with previous observations in humans, autophagy also increased with aging at subpopulation levels. Importantly, we found that only monocytes—specifically, nonclassical monocytes—displayed robust increased autophagic flux following amino acid withdrawal, underscoring the importance of population selection for measurement of autophagic flux during nutrient restriction studies in humans. Collectively, these data show PBMC population‐level analysis improves sensitivity of human autophagic flux measurement.


  • Open Access

    Autophagy across tissues of aging mice

    by Julian M. Carosi, Alexis Martin, Leanne K. Hein, Sofia Hassiotis, Kathryn J. Hattersley, Bradley J. Turner, Célia Fourrier, Julien Bensalem, Timothy J. Sargeant

    Autophagy is a ‘waste-disposal’ pathway that protects against age-related pathology. It is widely accepted that autophagy declines with age, yet the role that sex and diet-related obesity play during aging remain unknown. Here, we present the most comprehensive in vivo study of autophagic flux to date. We employed transgenic mice overexpressing tandem-florescent LC3B (RFP-GFP-LC3B) to measure autophagic flux in the blood (PBMCs), heart, and motor cortex neurons of aging mice that were fed regular chow or a high-fat diet for 6-, 12- or 18-months. In male mice, aging decreased autophagic flux in the heart, increased it in the blood, and had no effect in motor cortex neurons. Age-dependent changes autophagic flux were less pronounced in female mice. High-fat diet influenced autophagic flux in the blood and heart of male but not female mice. Overall, we uncovered sexual dimorphisms that underpin how autophagy changes with age across different tissues and in response to a high-fat diet.


  • Open Access

    Cell-type specific autophagy in human leukocytes

    by Linh Vp Dang, Alexis Martin, Julian M Carosi, Jemima Gore, Sanjna Singh, Timothy J Sargeant

    Autophagy is a naturally conserved mechanism crucial for degrading and recycling damaged organelles and proteins to support cell survival. This process slows biological ageing and age-related disease in preclinical models. However, there has been little translation of autophagy to the clinic, and we have identified a lack of measurement tools for physiological human autophagy as a barrier. To address this, we have previously developed a direct measurement tool for autophagy in pooled human peripheral blood mononuclear cells (PBMCs) in the context of whole blood. In order to better understand how autophagy behaves and changes in humans, we measured human autophagic flux using flow cytometry in 19 cell sub-populations in whole blood to retain physiological flux. Autophagic flux was different between different cell types, being highest in B lymphocytes and lowest in T lymphocytes and monocytes. Autophagic flux also varied with sex, being higher in monocytes in females compared with males. In keeping with previous observations in humans, autophagy also increased with ageing at sub-population levels. Importantly, we found that only monocytes – specifically, non-classical monocytes – displayed increased autophagic flux following amino acid withdrawal, underscoring the importance of population selection for measurement of autophagic flux during nutrient restriction studies in humans. Collectively, these data show PBMC population level analysis improves sensitivity of human autophagic flux measurement.


  • Open Access

    Autophagy across tissues of aging mice

    by Julian M. Carosi, Alexis Martin, Leanne K. Hein, Sofia Hassiotis, Kathryn J. Hattersley, Bradley J Turner, Célia Fourrier, Julien Bensalem, Timothy J. Sargeant

    Autophagy is a ‘waste-disposal’ pathway that protects against age-related pathology. It is widely accepted that autophagy declines with age, yet the role that sex and diet-related obesity play during aging remain unknown. Here, we present the most comprehensive in vivo study of autophagic flux to date. We employed transgenic mice overexpressing tandem-florescent LC3B (RFP-GFP-LC3B) to measure autophagic flux in the blood (PBMCs), heart, and motor cortex neurons of aging mice that were fed regular chow or a high-fat diet for 6-, 12- or 18-months. In male mice, aging decreased autophagic flux in the heart, increased it in the blood, and had no effect in motor cortex neurons. Age-dependent changes autophagic flux were less pronounced in female mice. High-fat diet influenced autophagic flux in the blood and heart of male but not female mice. Overall, we uncovered sexual dimorphisms that underpin how autophagy changes with age across different tissues and in response to a high-fat diet.


  • Autophagy captures the retromer-TBC1D5 complex to inhibit receptor recycling

    by Julian M. Carosi, Leanne K. Hein, Jarrod J. Sandow, Linh V. P. Dang, Kathryn Hattersley, Donna Denton, Sharad Kumar, Timothy J. Sargeant

    Retromer prevents the destruction of numerous receptors by recycling them from endosomes to the trans-Golgi network or plasma membrane. This enables retromer to fine-tune the activity of many signaling pathways in parallel. However, the mechanism(s) by which retromer function adapts to environmental fluctuations such as nutrient withdrawal and how this affects the fate of its cargoes remains incompletely understood. Here, we reveal that macroautophagy/autophagy inhibition by MTORC1 controls the abundance of retromer+ endosomes under nutrient-replete conditions. Autophagy activation by chemical inhibition of MTOR or nutrient withdrawal does not affect retromer assembly or its interaction with the RAB7 GAP protein TBC1D5, but rather targets these endosomes for bulk destruction following their capture by phagophores. This process appears to be distinct from amphisome formation. TBC1D5 and its ability to bind to retromer, but not its C-terminal LC3-interacting region (LIR) or nutrient-regulated dephosphorylation, is critical for retromer to be captured by autophagosomes following MTOR inhibition. Consequently, endosomal recycling of its cargoes to the plasma membrane and trans-Golgi network is impaired, leading to their lysosomal turnover. These findings demonstrate a mechanistic link connecting nutrient abundance to receptor homeostasis.


  • Receptor Recycling by Retromer

    by Julian M. Carosi, Donna Denton, Sharad Kumar, Timothy J. Sargeant

    The highly conserved retromer complex controls the fate of hundreds of receptors that pass through the endolysosomal system and is a central regulatory node for diverse metabolic programs. More than 20 years ago, retromer was discovered as an essential regulator of endosome-to-Golgi transport in yeast; since then, significant progress has been made to characterize how metazoan retromer components assemble to enable its engagement with endosomal membranes, where it sorts cargo receptors from endosomes to the trans-Golgi network or plasma membrane through recognition of sorting motifs in their cytoplasmic tails. In this review, we examine retromer regulation by exploring its assembled structure with an emphasis on how a range of adaptor proteins shape the process of receptor trafficking. Specifically, we focus on how retromer is recruited to endosomes, selects cargoes, and generates tubulovesicular carriers that deliver cargoes to target membranes. We also examine how cells adapt to distinct metabolic states by coordinating retromer expression and function. We contrast similarities and differences between retromer and its related complexes: retriever and commander/CCC, as well as their interplay in receptor trafficking. We elucidate how loss of retromer regulation is central to the pathology of various neurogenerative and metabolic diseases, as well as microbial infections, and highlight both opportunities and cautions for therapeutics that target retromer. Finally, with a focus on understanding the mechanisms that govern retromer regulation, we outline new directions for the field moving forward.


  • Rapamycin and Alzheimer disease: a hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease

    by Julian M Carosi, Timothy J Sargeant

    In 2019 we summarized work relating to the potential use of rapamycin for treating Alzheimer disease (AD). We considered the commentary necessary because use of rapamycin in people with AD is a very real prospect and we wanted to present a balanced view of the likely consequences of MTOR (mechanistic target of rapamycin kinase) inhibition in the AD brain. We concluded that use of rapamycin, an MTOR inhibitor that increases macroautophagy/autophagy, could hold promise for prevention of AD if used early enough. However, MTOR inhibition appeared ineffectual in resolving existing amyloid pathology in AD mouse models. In this View article, we update these observations with new studies that have used rapamycin in AD models and provide evidence both for and against its use in AD. We also discuss rapamycin in the light of new research that describes rapamycin-induced autophagic stress in the ageing brain and autophagic stress as the origin of the amyloid plaque itself. We conclude that rapamycin will have complex effects on the brain in AD. Further, we hypothesize that lysosomal degradative capacity in the brain will likely determine how effective or detrimental rapamycin will be as a treatment of AD.


  • Faculty Opinions recommendation of A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome.

    by Christopher Proud, Julian Carosi

    Transcription factor EB (TFEB) is a master transcriptional regulator of catabolic processes, including lysosome biogenesis and autophagy. The nuclear import of TFEB, and therefore its transcriptional activity, are blocked following its phosphorylation by mTORC1. mTORC1 also promotes anabolism by stimulating processes such as protein translation and ribosome biosynthesis through phosphorylation of its substrates, including 4E-BP1 and S6K1. mTORC1 activity is coordinated by growth factor and amino acid inputs; amino acids stimulate Rag GTPase-dependent recruitment of mTORC1 to the lysosome, where growth factor signals enable Rheb to activate its kinase activity toward (almost all) substrates. Unlike 4E-BP1 and S6K1, phosphorylation of TFEB by mTORC1 is insensitive to growth factor (serum) withdrawal and occurs independently of Rheb and is strictly amino acid-dependent. TFEB lacks a TOS motif, which is found on other substrates to permit their binding to the mTORC1 component Raptor to enable phosphorylation. Engineering a TOS motif onto TFEB renders its phosphorylation by mTORC1 growth factor-sensitive. Instead, TFEB interacts with active RagC which recruits it to the lysosome for phosphorylation by mTORC1. Loss of FLCN, a GTPase-activating protein for RagC/D impairs the phosphorylation of TFEB (but not S6K1 or 4E-BP1), and is rescued by the expression of active RagC. Loss-of-function mutations in FLCN cause Birt-Hogg-Dubé syndrome in humans, which manifests as a severe kidney disease and cancer. In this disease, mTORC1 is hyperactive; yet TFEB is unphosphorylated and also hyperactive. This paradox can be explained by increased TFEB-mediated expression of RagC/D, which would be inactive in the absence of FLCN, but able to support mTORC1 phosphorylation of substrates such as 4EBP1 and S6K1, but not TFEB. Remarkably, while kidney-specific knock-out of Flcn in mice reproduces major clinical features of Birt-Hogg-Dubé syndrome, such pathologies are completely absent in mice that also lack Tfeb. This work illustrates that not all mTORC1 substrates behave equally, and that specific inputs into the mTORC1 pathway may be connected to distinct - rather than generic - outputs. This revised mechanism of mTORC1 activation underpins the pathophysiology of a rare human disease.